Humacyte has announced that the US Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for a first-in-human clinical study of the coronary tissue engineered vessel (CTEV) in coronary artery bypass grafting (CABG). Humacyte plans to initiate a phase 2a study of the CTEV in CABG patients during the current quarter. […] The post Coronary tissue engineered vessel to be studied in first-in-human trial appeared first on Cardiovascular News .